[go: up one dir, main page]

WO2012050370A3 - Composition for preventing or treating rheumatoid arthritis containing a gamma secretase inhibitor as an active ingredient - Google Patents

Composition for preventing or treating rheumatoid arthritis containing a gamma secretase inhibitor as an active ingredient Download PDF

Info

Publication number
WO2012050370A3
WO2012050370A3 PCT/KR2011/007611 KR2011007611W WO2012050370A3 WO 2012050370 A3 WO2012050370 A3 WO 2012050370A3 KR 2011007611 W KR2011007611 W KR 2011007611W WO 2012050370 A3 WO2012050370 A3 WO 2012050370A3
Authority
WO
WIPO (PCT)
Prior art keywords
secretase inhibitor
gamma secretase
reduces
rheumatoid arthritis
preventing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2011/007611
Other languages
French (fr)
Korean (ko)
Other versions
WO2012050370A2 (en
Inventor
조동규
박종성
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sungkyunkwan University
Original Assignee
Sungkyunkwan University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020110100981A external-priority patent/KR101330184B1/en
Application filed by Sungkyunkwan University filed Critical Sungkyunkwan University
Publication of WO2012050370A2 publication Critical patent/WO2012050370A2/en
Publication of WO2012050370A3 publication Critical patent/WO2012050370A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to a composition for preventing or treating rheumatoid arthritis containing a gamma secretase inhibitor as an active ingredient. The gamma secretase inhibitor according to the present invention reduces the extent of arthritis induction and reduces the inflow of inflammatory cells into the knee joint, in a dose-dependent fashion, and also reduces the amount of cytokines and chemokines, and reduces the amount of expression of NICD (notch intracellular domain). Consequently, the gamma secretase inhibitor according to the present invention can be used as a medicinal product and a functional health food which is useful in the prevention or treatment of rheumatoid arthritis, since it regulates the activation, differentiation and growth of immune cells and hence has an outstanding effect in suppressing the production of NICD which plays a highly important role in notch signal transmission whereby inflammatory reactions occur.
PCT/KR2011/007611 2010-10-15 2011-10-13 Composition for preventing or treating rheumatoid arthritis containing a gamma secretase inhibitor as an active ingredient Ceased WO2012050370A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR20100100716 2010-10-15
KR10-2010-0100716 2010-10-15
KR1020110100981A KR101330184B1 (en) 2010-10-15 2011-10-05 Composition comprising gamma-secretase inhibitor for preventing or treating rheumatoid arthritis
KR10-2011-0100981 2011-10-05

Publications (2)

Publication Number Publication Date
WO2012050370A2 WO2012050370A2 (en) 2012-04-19
WO2012050370A3 true WO2012050370A3 (en) 2012-12-06

Family

ID=45938806

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2011/007611 Ceased WO2012050370A2 (en) 2010-10-15 2011-10-13 Composition for preventing or treating rheumatoid arthritis containing a gamma secretase inhibitor as an active ingredient

Country Status (1)

Country Link
WO (1) WO2012050370A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115364282A (en) * 2022-09-05 2022-11-22 东莞市人民医院 Dual-function vascular stent and preparation method thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050054633A1 (en) * 2003-09-09 2005-03-10 Alexander Flohr Malonamide derivatives
WO2009087130A1 (en) * 2008-01-11 2009-07-16 F. Hoffmann-La Roche Ag Use of a gamma-secretase inhibitor for treating cancer

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050054633A1 (en) * 2003-09-09 2005-03-10 Alexander Flohr Malonamide derivatives
WO2009087130A1 (en) * 2008-01-11 2009-07-16 F. Hoffmann-La Roche Ag Use of a gamma-secretase inhibitor for treating cancer

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LUISTRO, LEOPOLDO ET AL.: "Preclinical Profile of a Potent gamma-Secretase Inhibitor Targeting Notch Signaling with In vivo Efficacy and Pharmacodynamic Properties", CANCER RESEARCH, vol. 69, no. 19, 22 September 2009 (2009-09-22), pages 7672 - 7680 *

Also Published As

Publication number Publication date
WO2012050370A2 (en) 2012-04-19

Similar Documents

Publication Publication Date Title
EP4230623A3 (en) Pyridine compounds as allosteric shp2 inhibitors
WO2012112777A3 (en) Biosynthesis of human milk oligosaccharides in engineered bacteria
TN2012000428A1 (en) Bisaryl-bonded aryltriazolones and use thereof
MX346458B (en) Probiotic composition for oral health.
WO2010129285A3 (en) Antimicrobial compositions and related methods of use
PH12019500714A1 (en) Antiseptic-tolerant lactic acid bacteria
MX2012000827A (en) Particles incorporating antimicrobial agents.
EA033436B1 (en) 5-phenoxy-3h-pyrimidin-4-one derivatives and their use as hiv reverse transcriptase inhibitors
WO2012046030A3 (en) Phosphodiesterase inhibitors
UA109876C2 (en) Composition containing bifidobacterium longum cncm i-2618 for use in treatment or prevention of disorders related to immune system
GEP20207158B (en) Amide-substituted pyridinyltriazole derivatives and uses thereof
MX2012013703A (en) Modified c-3 betulinic acid derivatives as hiv maturation inhibitors.
PH12013500931A1 (en) Non-replicating probiotic micro-organisms protect against upper respiratory tract infections
EP1941892A3 (en) Anti-allergy lactic acid bacteria
MY159379A (en) Composition for human and/or animal nutrition, uses thereof and yeasts
SG184347A1 (en) Non-nucleoside reverse transcriptase inhibitors
MX365046B (en) Oral tablet formulation consisting of fixed combination of rosuvastatin and ezetimibe for treatment of hyperlipidemia and cardiovascular diseases.
WO2011159129A3 (en) Novel rhodanine derivatives, method for preparing same, and pharmaceutical composition for the prevention or treatment of aids containing the rhodanine derivatives as active ingredients
PH12013500735A1 (en) Powdered cereal compositions comprising non-replicating probiotic microorganisms
PH12013500811A1 (en) Extruded non-replicating probiotic micro-organisms and their health benefits
WO2008057300A3 (en) Trpvi antagonists and uses thereof
EP4272832A3 (en) Antimicrobial compounds, compositions, and uses thereof
GB201200858D0 (en) Prebiotic powder composition and uses thereof
WO2011149301A3 (en) A composition comprising the extract of physalis alkekengi var. francheti hort as an active ingredient for preventing and treating inflammatory diseases
PH12013500761A1 (en) Cysteine and food intake

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11832757

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11832757

Country of ref document: EP

Kind code of ref document: A2